Artiva Biotherapeutics (NASDAQ: ARTV) net income
Artiva Biotherapeutics reported a net loss of $83.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $65.4m. Earnings per share were −$3.43.
Artiva Biotherapeutics's best year of the last 3 was fiscal 2023. It reported a loss in 3 of those 3 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$83.9m | — | — | −$3.43 |
| 2024 | −$65.4m | — | −26,045.0% | −$5.81 |
| 2023 | −$28.7m | — | −85.8% | −$35.78 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Artiva Biotherapeutics net income compared with its sector
By net income for its latest fiscal year, Artiva Biotherapeutics ranks 323rd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 321st | Geron | −$83.5m | — |
| 322nd | Aquestive Therapeutics | −$83.8m | −188.1% |
| 323rd | Artiva Biotherapeutics | −$83.9m | — |
| 324th | Clover Health Investments | −$85.5m | −4.4% |
| 325th | MBX Biosciences | −$87.0m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Artiva Biotherapeutics
- How much did Artiva Biotherapeutics earn in fiscal 2025?
- Artiva Biotherapeutics reported a net loss of $83.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $65.4m.
- What are the earnings per share of Artiva Biotherapeutics?
- They were −$3.43 in fiscal 2025, compared with −$5.81 in fiscal 2024.
- Where does Artiva Biotherapeutics rank in its sector by net income?
- It ranks 323rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Artiva Biotherapeutics come from?
- From the annual report (Form 10-K) that Artiva Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Artiva Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Artiva Biotherapeutics: the Artiva Biotherapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.